ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. The company delivers a unique combination of technology, services and clinical consulting, built on a foundation of deep scientific and regulatory expertise.

ERT's systems are widely used by pharmaceutical and biotech companies innovating drug and device therapies to optimize clinical trial management, and to document safety and efficacy clinical outcomes data. ERT's solutions increase the accuracy and reliability of patient data and improve widely deployed solutions in healthcare areas such as Cardiac Safety, Respiratory Solutions and electronic Clinical Outcome Assessments (eCOA).

Since its inception in 1972, ERT has developed from a technology start-up to a company that today supports the conduct of thousands of clinical trials annually. This is achieved through the compilation of a variety of clinical outcome data from more than 5 million patients, in strict accordance with the standards defined by the major regulatory agencies.

Nordic Capital Fund VIII acquired ERT in 2016. In 2020, Nordic Capital, re-invested alongside Astorg and Novo through Fund IX. Building on ERT's leading technology platform and reputation for operational excellence, the new broadened ownership group, together with management, will invest in the continued development of the business with the aim of further expanding operational capabilities and selectively pursuing add-on investments to support future growth.

 

 

Sector

Sector Icon

Healthcare

Sector Icon

Tech & Payments

Key Information

Revenues Icon

Revenues 2019*

EUR 500 million

Employees Icon

Employees

1,930

Ownership Icon

Ownership

Nordic Capital Fund IX, co-controlling shareholding

Head Office Icon

Head office

Philadelphia, Pennsylvania, USA

Investment Icon

Investment date

2020

*Reported